Brian Rittenhouse

Peer reviewed publications

Rittenhouse B, Alolayan S, Segal A, Eguale T, Reply to Comment on: Rittenhouse BE, Alolayan S, Eguale T, Segal AR, Doucette J, Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was, Diabetes Obes Metab. 2024; 26: 5097-5106; DOI: 10.1111/dom.15851

Rittenhouse B, Eguale T, Perpetuating the Myth of Metformin Cost-effectiveness in the Diabetes Prevention Program, Diabetes Care (ACCEPTED 8/19/25; then rejected due to low priority; not published)

Beaulieu E, Rittenhouse B Economic Considerations of Office-Based Methadone as an Opioid Use Disorder Treatment Option: A Cost-Effectiveness Analysis and Methodological Comparison, Health Serv Outcomes Res Method (June 11, 2025) DOI: 10.1007/s10742-025-00349-6

Alolayan S, Eguale T, Segal, A, Doucette, J, Rittenhouse B, Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study, Am J Lifestyle Med (Jan. 21, 2025 online); DOI: 10.1177/15598276251315415

Rittenhouse BE, Nicod E, Rare Diseases: Economic Evaluation and Policy Issues, Value in Health (2024); 27)12):1635-1636; DOI: doi.org/10.1016/j.jval.2024.10.3803

Rittenhouse BE, Cost of/Burden of Illness Studies: Steps Backward? Value in Health (2024); 27(10): 1466-1467; DOI: 10.1016/j.jval.2024.07.023

Rittenhouse BE, Alolayan S, Eguale T, Segal AR, Doucette J, Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was, Diabetes Obes Metab. 2024; 26: 5097-5106; DOI: 10.1111/dom.15851

Rittenhouse B, Alolayan S, Eguale T, Segal A, Doucette J, The cost-effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply, Preventive Medicine. 178 (2024) DOI: 10.1016/j.ypmed.2023.107819

M Alsheikh, E Seoane-Vazquez, B Rittenhouse, ER. Fox, J Fanikos. A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis. Hospital Pharmacy. 2016, May 51(5), 370-375

Rittenhouse BE “Pricing Calculations” Neurology 2015 [electronic response to Hartung et al, “The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail Online letter, June 18, 2015 ; see also: authors’ response and Editor’s thanks, June 30, 2015, http://www.neurology.org/content/84/21/2185/reply#neurology_el;63821

D Nathwani, J. Li, D. Balan, R J. Willke, B. Rittenhouse, E Mozaffari, T Tang, M Tavakoli “Economic evaluation of linezolid versus teicoplanin for the treatment gram-positive bacterial infections in hospitalized patients in Europe: results from a multi-centre trial” International Journal of Antimicrobial Agents 2004 Apr, 23(4):315-24

H López, J Li,D. Balan, RJ. Willke, B Rittenhouse, E Mozaffari, T Tang “Economic evaluation of linezolid versus teicoplanin for the treatment gram-positive bacterial infections in hospitalized patients in South/Latin America: results from a multi-centre trial” Clinical Therapeutics 2003 Jun 25(6):1846-71.

JZ Li, RJ Willke, B. Rittenhouse, MJ Rybak “Effect of linezolid versus vancomycin on hospital length of stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococcus species: results from a randomized clinical trial”, Surgical Infections 2003 4(1): 45-58.

A Vinken ,Li J, Balan, D, Rittenhouse BE, Willke RJ, “Economic evaluation of linezolid, oxacillin and vancomycin in the empirical treatment of cellulitis in US hospitals: a decision analytical model” American Journal of Therapeutics 2003 Jul-Aug; 10(4):264-74

RJ Willke, Glick HA, Li J, Rittenhouse BE, “Effects of Linezolid on Hospital Length of Stay Compared to Vancomycin in Treatment of Methicillin-Resistant Staphylococcus Infections: An Application of Multivariate Survival Analysis”, Intl J Tech Assessment in Health Care 18:3 (2002), 540-554.

Li, J, Willke, RJ, Rittenhouse, BE, Glick H “Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococci species infections” Pharmacotherapy 2002; 22(2): 45S-54S.

A Vinken ,Li J, Balan, D, Rittenhouse BE, Willke RJ, Nathwani D, “Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model” J of Hospital Infections 2001; 49 (Supplement A): S13-S24

Zhiming Li, Z., Willke, RJ, Pinto, LA, Rittenhouse, BE, et al “Reduction in Hospital Length of Stay (LOS) in Patients with Known or Suspected Methicillin-Resistant Staphylococcus species Infections Treated with Linezolid Compared to Vancomycin: A Randomized, Multi-Center Trial” Pharmacotherapy 2001; 21(3): 263-274

Rittenhouse, B, Stinnett, A., Dulisse, B, et al. “An Economic Evaluation of Levofloxacin in the Outpatient Treatment of Adults with Community-Acquired Pneumonia” American Journal of Managed Care. 2000; 6(3):91-99.

Rittenhouse, B, Dulisse, B, Stinnett, A. “What Price Significance? The Effect of Price Estimates on Statistical Inference in Economic Evaluation” Health Economics. 1999; 8:213-19.

Rittenhouse, B, Stinnett, A., Dulisse, B, et al. “An Economic Evaluation of Levofloxacin in the Inpatient Treatment of Adults with Community-Acquired Pneumonia” Pharmacy & Therapeutics. 1999; 24(4):169-79.

Rittenhouse, B., Choiniere, M. “An economic evaluation of pain therapy after hysterectomy: patient-controlled analgesia versus regular intramuscular opioid therapy” Int. J Tech. Assess. Health Care. 1999; 15(3):548-62.

Choiniere, M. Rittenhouse, B. et al. “Efficacy and costs of pain therapy in hysterectomized patients: Comparison between patient-controlled analgesia and regular intramuscular opioid therapy.” Anesthesiology. 1998; 89:1377-88.

Rittenhouse B. "Exorcising Protocol-induced Spirits: Making the Clinical Trial Relevant for Economics." Medical Decision Making, 1997, 17(3):331-39.

Rittenhouse B. “Healthy Years Equivalents v. Time Trade Off: Resolving Ambiguity on Certainty and Uncertainty.”, International Journal of Technology Assessment in Health Care, 1997, 13(1): 35-48.

Rittenhouse B. “Is there a Need for Methods Standardization in Economic Evaluation?”, Medical Care. Supplement: Proceedings of “Standards for Economic Evaluation of Drugs: Issues and Answers.”1996;34(12):DS13-DS22.

Rittenhouse B. “The Standards Debate: What Have We Learned?”, Medical Care. Supplement: Proceedings of “Standards for Economic Evaluation of Drugs: Issues and Answers.” 1996;34(12):DS5-DS10.

Rittenhouse B. "A Novel Compliance Assessment Technique: The Randomized Response Interview.", International Journal of Technology Assessment in Health Care, 1996; 12(3):498-510.

Rittenhouse, B. "Respondent-Specific Information from the Randomized Response Interview."
J Clin Epidemiol (1996); 49(5):545-49.

Rittenhouse B. "Another Deficit Problem: The Deficit of Relevant Information when Clinical Trials are the Basis for Pharmacoeconomic Research." Journal of Research in Pharmaceutical Economics (1996: 7(3) pp. 3-15).

Rittenhouse B. "The Relevance of Searching for Effects Under a Clinical Trial Lamp Post: A Key Issue." Medical Decision Making 1995; 15(4): 348-357.

Rittenhouse B. "Potential Inconsistencies Between Cost-Effectiveness and Cost-Utility Analyses: An Upstairs/Downstairs Socioeconomic Distinction." International Journal of Technology Assessment in Health Care 1995; 11(2):365-376.

Rittenhouse B. "Teaching the Tools of Pharmaceutical Care Decision-Analysis." American Journal of Pharmaceutical Education 58 (Winter 1994): 431-36.

Rittenhouse B. "Economic Incentives and Disincentives for Efficient Prescribing." Pharmacoeconomics 1994; 6(3):222-232.

Grabenstein J, Hartzema A, Guess H, Johnston W, Rittenhouse B. "Community Pharmacists as Immunization Advocates: Cost Effectiveness of a Cue to Influenza Vaccination." Medical Care 1992; 30(6).

Books/Book Chapters/Monographs

Morris-Blank C. and Rittenhouse B. (Eds.) Medical Care, Supplement: Proceedings of “Standards for Economic Evaluation of Drugs: Issues and Answers,” 1996.

Rittenhouse B. The Uses of Models in the Economic Evaluation of Medicines, Office of Health Economics, London, October, 1996.

Rittenhouse B. "Designing and Conducting Cost-Effectiveness and Cost-Minimization Analyses." In: B. Spilker, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Pub. 1996.

Rittenhouse B, O'Brien B. "Threats to the Validity of Pharmacoeconomic Analyses Based on Clinical Trial Data." In: B. Spilker, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Pub. 1996.

Rittenhouse B. Issues in the Economic Evaluation of Pharmaceuticals. Japanese Journal of Health Economics and Policy (Supplement) Institute for Health Economics and Policy, Tokyo, Japan, 1995.

Rittenhouse B. Interview with Dr. Philip G. Boysen on Economic Evaluation Issues for Point Counterpoint: Controversial Issues Confronting the Intensive Care Specialist, 4(4), 1996.

Rittenhouse B. “Gesundheitsökonomie - Bewertung des Screenings und seiner Nutzeffekte.” (Health Economics: The Economics of Screening and Outcome Valuation) In: P. Faul and J. E. Altwein (eds.), Screening des Prostatakarzinoms. Springer-Verlag, Berlin, 1995.

Rittenhouse B. Interview with Shunya Ikeda (discussion of economic evaluation issues for Japanese Medical Association), JAMIC Journal, August 1995:34-39.

Rittenhouse B. Review of L. Russell’s Educated Guesses: Making Policy about Medical Screening Tests. University of California Press, Berkeley, 1994. In: Iryo Keizai Kenkyu Kikou Letter (Institute for Health Economics and Policy Newsletter), Tokyo, Japan; No. 20, June 1995.

Rittenhouse B, Erickson P. Pharmacoeconomic and Quality of Life Evaluations, Schering-Plough, Kenilworth, NJ, 1992.

Brandt A, Rittenhouse B, eds. Guide to the Socioeconomic Analysis of Medical Therapies, CIBA-GEIGY, Pharma Economics, Basel, January 1990.

Rittenhouse B. Introduction to Economic Evaluation: Contributions to Health-Care Policy and Economics. CIBA-GEIGY, Pharma Policy and Economics, March 1989.

Accepted/Published Refereed Abstracts (only those since MCPHS employment included)

Rittenhouse B, Alolayan S, Eguale T, Segal A, Baseline risk heterogeneity in cost-effectiveness analysis of the diabetes prevention program, accepted for a poster presentation at ISPOR Europe conference, Glasgow, 2025
POSTER: https://www.ispor.org/docs/default-source/cti-meeting-21305-documents/44ea39c9-52b1-4be7-a0b1-96bbad6f2668.pdf?sfvrsn=bddc1937_0

Mikhaylova M, Rittenhouse B, The Institute for Clinical and Economic Review’s Incorrect Use of Incremental Cost-Effectiveness Ratios, ISPOR North American conference, Montreal, 2025; Value in Health Vol 28 (6) Suppl 1, July 2025, EE175, p. S94
POSTER: https://www.ispor.org/docs/default-source/cti-meeting-21021-documents/86e3116c-7445-4cb9-b7d0-fcf1b3942c2b.pdf?sfvrsn=aa055236_0

McCord S, Rittenhouse B, Frequency of ICER Miscalculation and Misinterpretation in Published Cost-Effectiveness Analyses Comparing More Than Two Alternatives, ISPOR North American conference, Montreal, 2025 (Best Student Presentation award); Value in Health Vol 28 (6) Suppl 1, July 2025, P57, p.S20
PRESENTATION: https://www.ispor.org/docs/default-source/cti-meeting-21021-documents/9e16e7d9-1346-4b51-aaba-e4940f0eed7d.pdf?sfvrsn=330ff8ba_0

Rittenhouse B, Willke R, Does One Comparator Fit All Scenarios? an Example from the Institute for Clinical and Economic Review’s 2023 Assessment of Relapsing-Remitting Multiple Sclerosis, ISPOR North American conference, Atlanta, 2024

Rittenhouse B, Beaulieu E, Addressing Decision Uncertainty in a Cost-Effectiveness Model of Opioid Use Disorder Treatments: Estimating the Value of Information and the Sample Size to Provide It, ISPOR North American conference, Atlanta, 2024

Beaulieu E, Rittenhouse B, Method Matters: Cost-Minimization Versus Cost-Effectiveness Frameworks in Assessing Opioid Use Disorder Treatments; Annual European ISPOR Conference, Copenhagen, 2023; top 5% Finalist

Patel U, Eguale T, Rittenhouse B, Yunusa I, Kandikatla R, Fathima A, Signal Detection Using Data from FDA Adverse Event Reporting System (FAERS): Infections in Biologics Vs Biosimilars; ISPOR North American conference, Boston, 2023

Paredes J, Rittenhouse B, Eguale T, Segal A, Doucette J, Correcting a Cost-Effectiveness Analysis (CEA) with Suggestions on Ways of Avoiding Misinterpretations and Calculating Errors Associated with Them: The Singapore Diabetes Prevention (CEA); ISPOR North American conference, Boston, 2023

Beaulieu E, Rittenhouse B Visualizing Joint Costs and Effects for Multiple Alternatives within Cost Effectiveness Analyses: Cost-Disutility Versus Traditional Cost-Effectiveness Planes in an Economic Evaluation of Opioid Use Disorder Treatments (poster presentation ISPOR North American conference 2022)

Beaulieu E, Rittenhouse B Advantages of Visualizing NET Loss Curves in Cost Effectiveness Analyses: An Example Comparing Opioid Use Disorder Treatment Alternatives; ISPOR North American conference 2022

Paredes J, Rittenhouse B The Singapore Diabetes Prevention Program Cost-Effectiveness Analysis Revisited: Proper Methods Overturn Previous Conclusions; ISPOR North American conference 2022

Paredes J, Rittenhouse B Transparency and Utility of Using NET Monetary Benefit (NMB) Analysis over Incremental Cost-Effectiveness Ratios (ICERS): The Case of the Singapore Diabetes Prevention Program Cost-Effectiveness Analysis (CEA); ISPOR North American conference 2022

Pretorius C, Rittenhouse B, Eguale T, Kallich J A RE-Examination of a Cost-Minimization Analysis in Multiple Sclerosis: Assessing Biases from the Inaccurate Assumption of Equal Effectiveness Using Probabilistic Sensitivity Analysis (PSA); ISPOR North American conference 2022

Pretorius C, Rittenhouse B, Eguale T, Kallich J A Re-Examination of a Cost-Minimization Analysis in Multiple Sclerosis: Assessing Biases from the Inaccurate Assumption of Equal Effectiveness; ISPOR North American conference 2022

Puskuru S, Rittenhouse B, Eguale T, Kallich J A Reexamination of Drug Costs for Cetuximab and Panitumimab in Metastatic Colorectal Cancer: Assessing the Influence of Drug Vial Splitting; ISPOR North American conference 2022

Sultan I, Syed SS, Fathima, A, Farag H, Yunusa I, Doucette J, Rittenhouse B, Eguale T Overall Mortality Among Patients with Hemophilia: A Systematic Review and Meta-Analysis; ISPOR North American conference 2022

Sultan I, Syed SS, Fathima, A, Farag H, Yunusa I, Doucette J, Rittenhouse B, Eguale T Cause-Specific Mortality Among Patients with Hemophilia: A Systematic Review and Meta-Analysis; ISPOR North American conference 2022

Gebrehiwet P, Kallich J, Rittenhouse B A systematic review of QWB and SF-6D: a preference-based instruments used to measure health related quality of life; Annual North American ISPOR Conference, Orlando, 2020

Gebrehiwet P, Eguale T, Segal A, Rittenhouse B The diabetes prevention program (DPP) quality of well being (QWB) utility measures and missing data considerations: available case analysis (ACA) vs. Manski lower and upper bounds (LMB and UMB) results for utilities and quality adjusted life years (QALYS); Annual North American ISPOR Conference, Orlando, 2020

Gebrehiwet P, Eguale T, Segal A, Rittenhouse B Quality adjusted life years (QALYs) in the diabetes prevention program (DPP) using quality of well being (QWB) and SF-6D instruments in same sample: complete case analysis; Annual North American ISPOR Conference, Orlando, 2020

Gebrehiwet P, Eguale T, Segal A, Rittenhouse B Multivariate logistic regression applied to clinical effectiveness in the diabetes prevention program (DPP); Annual North American ISPOR Conference, Orlando, 2020

Gebrehiwet P, Eguale T, Segal A, Rittenhouse B Quality adjusted life years (QALYs) in the diabetes prevention program (DPP): quality of well being (QWB) versus SF-6D instruments; Annual North American ISPOR Conference, Orlando, 2020

Gebrehiwet P, Eguale T, Segal A, Rittenhouse B The diabetes prevention program (DPP) quality of well being (QWB) and SF-6D utility measures and missing data considerations: available case analysis (ACA) vs. Manski lower and upper bounds (LMB and UMB) results for utilities and quality adjusted life years (QALYs) ; Annual North American ISPOR Conference, Orlando, 2020

Gebrehiwet P, Eguale T, Segal A, Rittenhouse B The diabetes prevention program (DPP) quality of well being (QWB) utility measures and missing data considerations: available case analysis (aca) vs. multiple imputation (MI) results for utilities and quality adjusted life years (QALYs); Annual North American ISPOR Conference, Orlando, 2020

Rittenhouse, B, Beaulieu E Difference in precision of retention estimates for mandated versus patient-chosen medication-assisted treatment (MAT) alternatives for opioid use disorder (OUD) Annual European ISPOR Conference, Milan, 2020

Beaulieu E, Rittenhouse, B Medications for Opioid Use Disorder: The Advantage of Office-Administered Methadone in a Cost-Effectiveness Framework; Annual European ISPOR Conference, Milan, 2020

Rittenhouse, B Importance of uncertainty in mean score estimates of one survey question about test accuracy: American College of Medical Genetics (ACMG) recommendations for newborn screening (NBS) in medium chain ketoacyl-coa thiolase deficiency (MCKAT); Annual European ISPOR Conference, Copenhagen, 2019

Ou Z, Wat R, Gebrehiwet P, Beaulieu E, Lim-Watson M, Rittenhouse B, Cost-effectiveness analysis of phenytoin versus levetiracetam for early seizure pharmacoprophylaxis after traumatic brain injury: patient perspective ; Annual North American ISPOR Conference, 2019; Value in Health, Volume 22, Issue S1 (2019 May)

Beaulieu E, Hariharan D, Gebrehiwet P, McCord S K, Doucette J, Rittenhouse B, Adherence of 2017-published cost-effectiveness analysis (CEA) articles to methodological standards for incremental cost-effectiveness ratios (ICERs) and other methods-oriented quality attributes; Annual North American ISPOR Conference, 2019; Value in Health, Volume 22, Issue S1 (2019 May)

Monina Lahoz, PhD; Lana Camiel Dvorkin, PharmD ; Gerard D’Souza, PhD ; Tewodros Eguale, MD, PhD; Paul Kiritsy, PharmD;; Matthew Machado; Jennifer Prisco, PharmD; Brian Rittenhouse, PhD; Anela Stanic, PharmD; Andrew Szumita, PharmD, Towards better assessment of educational outcomes through the mapping of exam questions, AACP Annual Meeting, July 2019

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse, Heterogeneity of treatment effect in the diabetes prevention program: high baseline risk of developing diabetes may provide a place for metformin in prediabetes treatment that using overall sample average costs and effects masks; Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018 (Value in Health, Vol 21, S132-3, October 2018)

M. Algarni, B. Rittenhouse, American college of medical genetics (ACMG) newborn screening (NBS) recommendations: sensitivity to accounting for reported missing data in the case of glutaric aciduria II (GAII), Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018 (Value in Health, Vol 21, S271, October 2018)

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse, Re-analysis of the diabetes prevention program 3 year cost-effectiveness analysis (CEA) using identical data but proper methods questions its conclusions, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018 (Value in Health, Vol 21, S132, October 2018)

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse , Re-analysis of the diabetes prevention program (DPP) 3 year cost-effectiveness analysis (CEA) using identical data but proper QALY calculations may revive its metformin conclusions, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018 (Value in Health, Vol 21, S132, October 2018)

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse, Reevaluating a 10 year cost-effectiveness analysis (CEA) of the diabetes prevention program outcomes study (DPP/DPPOS): clarifying the previous confusion, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018 (Value in Health, Vol 21, S133, October 2018)

S. Alolayan, T. Eguale, A. Segal, J. Doucette, B. Rittenhouse , Can missing data boundary estimates cast doubt on previous conclusions reevaluating a 10 year cost-effectiveness analysis (CEA) of the diabetes prevention program study (DPP/DPPOS)?, Accepted, but not presented at Annual European ISPOR Conference, Barcelona, November 2018 (Value in Health, Vol 21, S374, October 2018)

D. Hariharan, K. Daniels, R. Kodeih, J. Amamoo, I. Sultan, B. Rittenhouse, A cost effectiveness analysis (CEA) of phenytoin (PHT) versus levetiracetam (LEV) for early seizure pharmacoprophylaxis after traumatic brain injury (TBI) from a US institutional perspective: an upgrade of a cost minimization analysis (CMA); ISPOR North American Annual Meeting, May 2018, Baltimore, MA

A. Alfraih, B, Rittenhouse, Calculating appropriate ICERs in diabetes prevention program (DPP) cost-effectiveness and overturning misleading conclusions regarding optimal treatment; ISPOR North American Annual Meeting, May 2018, Baltimore, MA (Value in Health, Vol 21, S75, May 2018)

A. Redlich, B. Rittenhouse, Examining the effect of missing data on the ACMG newborn screening criteria of least consensus for carnitine palmitoyltransferase II deficiency (CPT II); ISPOR North American Annual Meeting, May 2018, Baltimore, MA (Value in Health, Vol 21, S132, May 2018)

M. Algarni, B. Rittenhouse, A systematic review of cost-effectiveness analysis studies in newborn screening (NBS); ISPOR North American Annual Meeting, May 2018, Baltimore, MA (Value in Health, Vol 21, S111-12, May 2018)

B. Rittenhouse, Accounting for known unknowns in the American College of Medical Genetics (ACMG) recommendations for NBS: policy implications of accounting for uncertainty in assessment in the case of medium chain ketoacyl-coa thiolase deficiency (MCKAT) newborn screening (NBS); ISPOR North American Annual Meeting, May 2018, Baltimore, MA (Value in Health, Vol 21, S175, May 2018)

R. Kodeih, B. Rittenhouse, American College of Medical Genetics (ACMG) recommendations for newborn screening (NBS) for biotinidase deficiency (BIOT): the influence of uncertainty due to missing data; ISPOR North American Annual Meeting, May 2018, Baltimore, MA (Value in Health, Vol 21, S174, May 2018)

K. Daniels, B. Rittenhouse, The analysis of missing data around the American College of Medical Genetics (ACMG) recommendations for newborn screening (NBS) of maple syrup urine disease (MSUD) ; ISPOR North American Annual Meeting, May 2018, Baltimore, MA (Value in Health, Vol 21, S260, May 2018)

Alsumali A, Al-Hawage A, Rittenhouse B, Seoane E, Eguale T. Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Bariatric Surgery. ISPOR North American Annual Meeting, May 2017, Boston, MA

Alsumali A, Eguale T, Bairdain S, Rittenhouse B, Seoane E, Samnaliev M. Cost Effectiveness of Bariatric Surgery for Morbid Obesity in USA. ISPOR North American Annual Meeting, May 2017, Boston, MA

Alsheikh M, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Defects of Biopterin Cofactor Biosynthesis (BIOPT BS) Using Manski Bounds and Bootstrapping. ISPOR North American Annual Meeting, May 2017, Boston, MA

Ndikumukiza C, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Hypermethioninemia (MET). ISPOR North American Annual Meeting, May 2017, Boston, MA

Moon J, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Medium/Short Chain L-3-OH ACYL-COA DH Deficiency (M/SCHAD). ISPOR North American Annual Meeting, May 2017, Boston, MA

Hariharan D, Rittenhouse B. Examining Uncertainty around the American College of Medical Genetics (ACMG) Recommendations for Newborn Screening (NBS) for Cystic Fibrosis (CF). ISPOR North American Annual Meeting, May 2017, Boston, MA (Value in Health, Vol 20(9), A525-526, October-November 2017)

Alolayan SO, Rittenhouse B. Clarifying Conclusions from a Cost-Effectiveness Analysis of the Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS). ISPOR North American Annual Meeting, May 2017, Boston, MA

Alharbi A, Rittenhouse B (2016) Examining uncertainty around American College of Medical Genetics (ACMG) recommendations for newborn screening for citrullenimia type 2 (CIT II) 2016 SMDM Annual North American meeting Vancouver, BC, Canada; https://smdm.confex.com/smdm/2016bc/webprogram/Paper10184.html

Bojan B, Rittenhouse B, (2016) Examining uncertainty around American College of Medical Genetics (ACMG) recommendations for newborn screening for galactose epimerase deficiency (GALE), Value in Health 19(3) A38, ISPOR 2016 North America conference

Yang K, Rittenhouse B, (2016) Impact of missing data in criteria of least consensus on ACMG newborn screening recommendations for short-chain acyl-coa dehydrogenase deficiency, Value in Health 19(3) A38, ISPOR 2016 North America conference

Algatan, R Rittenhouse B, (2016) Examining uncertainty around the American College of Medical Genetics (ACMG) recommendation for newborn screening for 2-methylbutyryll-coa dehydrogenase deficiency (2MBG), Value in Health 19(3) A39, ISPOR 2016 North America conference

Alharbi, A, Rittenhouse B, (2016) Examining uncertainty around American College of Medical Genetics recommendations for newborn screening for citrullenimia type 2 using Manski bounds, Value in Health 19(3) A307, ISPOR 2016 North America conference

Alotaibi A, Alsheikh M, Mahida SR, Rittenhouse B (2015), Exploring cost-effectiveness heterogeneity by state: Using state-level vs. national disease incidence in newborn screening (NBS) cost-effectiveness analysis of congenital adrenal hyperplasia (CAH), Value in Health 18(7) A755, 18^th Annual European ISPOR Conference, 2015, Milan, Italy

Alzarea A, Alolayan S, Almutairi H, Alqahtani SS, Rittenhouse B (2015), Re-evaluating the cost-effectiveness of screening for congenital adrenal hyperplasia (CAH): The sensitivity to choice of distributions in probabilistic sensitivity analyses (PSAs) Value in Health 18(7) 18^th Annual European ISPOR Conference, 2015, Milan, Italy

Alnafesah A, Rittenhouse B (2015), Variation in state-level vs. national incidence in rare genetic disease: A Monte Carlo simulation to examine sampling variation as a primary explanation in congenital adrenal hyperplasia Value in Health 18(7) 18^th Annual European ISPOR Conference, 2015, Milan, Italy

Almutairi, R, Rittenhouse B (2015) “ Getting the full picture: the importance of extrapolating beyond the data” Value in Health 18(3) A10-A11, ISPOR 2015 North America conference

Algarni, M Almutairi H, Rittenhouse B (2015) “Why ask if you know? ACMG’s potential errors in making newborn screening (NBS) recommendations from using surveyed opinions for incidence scoring when actual data are available” Value in Health 18(3) A305-A306, ISPOR 2015 North America conference

Rittenhouse B (2014) “The effect of a likely overemphasis on efficiency-related test attributes on ACMG recommendations for newborn screening (NBS)” Value in Health 17(7) A582, ISPOR Europe 2014 conference

Mahida S, Algarni M and Rittenhouse B (2014) “Effect of excluding non-patient benefits as an element on ACMG newborn screening (NBS) recommendations” Value in Health 17(7) A541, ISPOR Europe 2014 conference

Rittenhouse B “The importance of fact over opinion in choice of conditions to be recommended for newborn screening (NBS)” Value in Health 17(3) A237, ISPOR North America 2014 conference

Alotaibi A, Ansari K and Rittenhouse B “Changes and variation in conditions for newborn screening: state-specific conditions screened vs. ACMG recommendations contrasted with Europe”, Value in Health 17(3) A235, ISPOR North America 2014 conference

Alotaibi A and Rittenhouse B (2014) “Estimated Error in Using National Incidence Figures vs. State Estimates for Rare Disease Calculations of Estimated Cases and Cost per Case Detected in Newborn Screening (NBS): Congenital Adrenal Hyperplasia (CAH) and Congenital Hypothyroidism (CH)” Value in Health 17(3), A236; ISPOR North America 2014 conference